A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Barclays has nudged Vertex Pharmaceuticals’ price target to $499, despite a mixed bag in its Q1 performance. Vertex saw a 3% ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.77% to 5,606.91 ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

The Board of Directors of Vertex Securities Limited, at its meeting held today have approved the financial results of the ...

Lucent Industries Limited has entered into a partnership agreement with Clusterdev Technologies Private Limited, which provides ...